ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen

ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen

Source: 
Fierce Pharma
snippet: 

When Ipsen announced last week that it wanted in on Exelixis' Cabometyx for thyroid cancer, the company pegged that move to the oncology drug's promising late-stage trial results. Now, Exelixis is offering up more details of that very trial.